Modeling quantifies in vivo neutralization, Fc-mediated killing, and resistance in human clinical trials of five anti-HIV broadly neutralizing antibodies.

10-1074 - National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead

3BNC117 - Rockefeller University, Cornell University, Frontier Biotech, Gilead

VRC07-523LS - National Institute of Allergy and Infectious Diseases, IAVI, TaiMed Biologics

VRC01LS - National Institutes of Health, Xencor

VRC01 - Acuitas Therap

http://www.ncbi.nlm.nih.gov/pubmed/42367850

Alan S Perelson; Daniel B Reeves; E Fabian Cardozo-Ojeda; Jonah Hall; Joshua T Schiffer; Lucero Rodriguez Rodriguez; Rebecca M Lynch

Jun 30, 2026